A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Dovitinib (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2016 Status changed from active, no longer recruiting to discontinued due to decision made by company to cease development of dovitinib
- 11 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.